Kalsi Jas, Harland Stephen J, Feneley Mark R
UCLH NHS Foundation Trust, London, UK.
Expert Opin Drug Deliv. 2008 Jan;5(1):137-45. doi: 10.1517/17425247.5.1.137.
This article reviews the use and application of electromotive drug administration for the intravesical treatment of bladder cancer. Strong evidence supports the use of passive intravesical chemotherapy in the management of non-muscle invasive bladder cancer. More recently, two published randomised trials have shown therapeutic advantage with protocols that use electromotive drug administration to enhance urothelial penetration of intravesical mitomycin C. The results suggest that the passive intravesical administration of chemotherapeutic drugs may be suboptimal. Further studies are required to demonstrate the feasibility and advantage of electromotive intravesical mitomycin C in the wider uro-oncological community.
本文综述了电动药物给药在膀胱癌膀胱内治疗中的应用。有力证据支持在非肌层浸润性膀胱癌的治疗中使用被动膀胱内化疗。最近，两项已发表的随机试验表明，采用电动药物给药方案增强膀胱内丝裂霉素C的尿路上皮渗透具有治疗优势。结果表明，化疗药物的被动膀胱内给药可能并非最佳选择。需要进一步研究以证明电动膀胱内丝裂霉素C在更广泛的泌尿肿瘤学界的可行性和优势。
